Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 3/20 | 0.49 |
| ▸ | BTK | Q06187 | 3/20 | 0.47 |
| ▸ | LYN | P07948 | 2/20 | 0.47 |
| ▸ | TXK | P42681 | 2/20 | 0.47 |
| ▸ | SYK | P43405 | 2/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14633934 | 0.90 | BTK (0.49) | EPHB4BTKLYNTXKSYK | |
| SCHEMBL14634174 | 0.88 | RIPK2 (0.49) | EPHB4BTKLYNTXKSYK | |
| SCHEMBL14633535 | 0.87 | GRM4 (0.46) | EPHB4BTKLYNTXKSYK | |
| SCHEMBL14634250 | 0.86 | TRPA1 (0.48) | EPHB4BTKLYNTXKSYK | |
| SCHEMBL2512099 | 0.85 | BTK (0.50) | EPHB4BTKLYNTXKSYK | |
| SCHEMBL14633840 | 0.85 | GRM4 (0.48) | EPHB4BTKLYNTXKSYK | |
| SCHEMBL14650714 | 0.85 | BTK (0.48) | EPHB4BTKLYNTXKSYK | |
| SCHEMBL14634059 | 0.83 | EPHB4 (0.55) | EPHB4BTKLYNTXKSYK | |
| SCHEMBL14633919 | 0.83 | BTK (0.43) | EPHB4BTKLYNTXKSYK | |
| SCHEMBL14633944 | 0.82 | BTK (0.45) | EPHB4BTKLYNTXKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552211-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-02-06 | — | — | EP | disclosed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| WO-2011120025-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | EPHB4 2462/4885BTK 215/4885LYN 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.